Trials / Completed
CompletedNCT02143570
Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Universidad de Valparaiso · Academic / Other
- Sex
- Female
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
Overactive bladder is a common problem among adult women. Darifenacin is an antimuscarinic drug that is frequently used as part of the management of the condition. However, current evidence backing its use is limited. This study aims to address Darifenacin's effectiveness in adjunct to physiotherapy in treating symptoms due to overactive bladder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Darifenacin | Darifenacin will be prescribed in a starting dose of 7.5mg, once daily. This dose may be increased to 15mg a day in cases with refractory symptoms. |
| PROCEDURE | Physiotherapy | All patients will received a tailored pelvic floor exercise programme as part of the standard of care of overactive bladder at the study centre. This intervention will be mainly comprised of biofeedback stimulation techniques. |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2016-04-01
- Completion
- 2016-04-01
- First posted
- 2014-05-21
- Last updated
- 2016-05-02
Locations
1 site across 1 country: Chile
Source: ClinicalTrials.gov record NCT02143570. Inclusion in this directory is not an endorsement.